Prostate cancer is the second leading reason behind cancer-related loss of life in men generally in most American countries. Medication Administration (FDA) on Apr 28 2011 in conjunction with prednisone for the treating metastatic castration-resistant prostate cancers (mCRPC) that was previously treated with docetaxel. The acceptance of the agent was predicated on a multinational randomized… Continue reading Prostate cancer is the second leading reason behind cancer-related loss of